Category: Health Science
-
![Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million]()
Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research and development, but instead bring over drugs that are already licensed in Western Europe to North America which sees them carve out a nice and profitable…
-
![Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector]()
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost. According to a recent study which tracked the success rates of clinical drug development through to FDA approval between 2006-2015, just 9.6% of the drug candidates…
-
![Medexus (MDP.T) resubmits Treosulfan NDA to FDA]()
Medexus (MDP.T) resubmits Treosulfan NDA to FDA
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted its New Drug Application (NDA) for treosulfan to the U.S. Food and Drug Administration. This submission was a response to the FDA request to submit information…
-
![Three biotech stocks you may have missed]()
Three biotech stocks you may have missed
Kezar Life Sciences Inc. Between 2020 and 2021, year-over-year (YoY) funding in the biotech market increased by an impressive 39.6%. Currently, some of the biggest trends in this market include personalized medicine, drug research, artificial intelligence, big data, and synthetic biology. In total, the biotech market is expected to increase from USD$852.88 billion in 2020,…
-
![Revive Therapeutics (RVV.C) clears FDA hurdles]()
Revive Therapeutics (RVV.C) clears FDA hurdles
Last year Big Pharma unleashed 1,500 lobbyists to Washington, DC, who then cut cheques for $177 million to keep drug costs high. The lobbyists deserve bonuses. The average U.S. citizen spends $1,200 per year on prescription medicines, while people in other western countries spend an average of $550/year. Public health data indicates that the gluttony…
-
![Stocks to Watch: Lexaria Bioscience (LEXX.Q) sees gains]()
Stocks to Watch: Lexaria Bioscience (LEXX.Q) sees gains
Special Delivery Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of orally-delivered drugs, DehydraTECH has demonstrated effectiveness in improving delivery through human skin for the potential development of topically-administered products such as patches. Through various animal studies evaluating the quantity…
-
![ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%]()
ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%
A Need for Alternatives $54.898M Market Capitalization ERYTECH Pharma (ERYP.Q) announced today that the Company has sold its US manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. Under the terms of the agreement, Catalent has agreed to purchase ERYTECH’s US facility for a total consideration of $44.5 million. That’s…
-
![Market positivity leads to psychedelic space love, is the sector slump over? – Today’s Idea]()
Market positivity leads to psychedelic space love, is the sector slump over? – Today’s Idea
We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The appreciation isn’t absolute, but many companies in the space are experiencing a much-needed bump. I want to focus on four psychedelics companies, each pursuing a different…
-
![Perimeter Medical Imaging AI (PINK.V) Fights Back Against Cancer]()
Perimeter Medical Imaging AI (PINK.V) Fights Back Against Cancer
An Insatiable Disease Cancer is a grim disease, feeding off numerous sources including tobacco, infections, environmental pollution, occupational carcinogens, and radiation, among others. Whether directly or indirectly, everyone has experienced the effects of cancer at some point in their life. Wincing pain, weight loss, and an overwhelming feeling of fatigue all plagued my mom as…
-
![Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector]()
Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the evidence that they’re actually serious about getting products on shelves? How many startup drug companies at will never see the inside of a laboratory? Why? The…
